Holen Sie sich die Stockscreener-App
131.81
0.36%
0.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$131.38
Offen:
$131.46
24-Stunden-Volumen:
1.56M
Relative Volume:
0.26
Marktkapitalisierung:
$229.41B
Einnahmen:
$43.11B
Nettoeinkommen (Verlust:
$13.94B
KGV:
16.48
EPS:
7.9963
Netto-Cashflow:
$6.78B
1W Leistung:
-0.88%
1M Leistung:
-1.40%
6M Leistung:
+3.04%
1J Leistung:
+12.46%
1-Tages-Spanne:
$131.23
$132.56
1-Wochen-Bereich:
$130.87
$135.12
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
131.81 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.58 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
368.80 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.14 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Sinocare Challenges Abbott's Glucose Monitor Patents - Law360
Mizuho Adjusts Price Target on Abbott Laboratories to $140 From $135, Maintains Neutral Rating - MarketScreener
Why analysts recommend Abbott Laboratories (ABL) stock2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - newser.com
Abbott Laboratories To Go Ex-Dividend On October 15th, 2025 With 0.59 USD Dividend Per Share - 富途牛牛
Abbott Laboratories (ABT) Q3 Earnings Report Preview: What To Look For - FinancialContent
Ex-Dividend Reminder: Abbott Laboratories, AbbVie and ARMOUR Residential REIT - Nasdaq
Vest Financial LLC Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
MOKAN Wealth Management Inc. Has $2.99 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Welch Group LLC Grows Position in Abbott Laboratories $ABT - MarketBeat
Pathway Financial Advisors LLC Sells 3,588 Shares of Abbott Laboratories $ABT - MarketBeat
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Volatility clustering patterns for Abbott LaboratoriesWeekly Trend Report & Fast Gain Stock Tips - newser.com
Mitchell Sinkler & Starr PA Sells 70,137 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Natural Investments LLC - MarketBeat
Abbott Laboratories $ABT Stock Holdings Increased by Fifth Third Wealth Advisors LLC - MarketBeat
Cwm LLC Raises Position in Abbott Laboratories $ABT - MarketBeat
DSM Capital Partners LLC Sells 81,763 Shares of Abbott Laboratories $ABT - MarketBeat
Johnson Investment Counsel Inc. Lowers Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Raised by Concurrent Investment Advisors LLC - MarketBeat
Sivik Global Healthcare LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Those who invested in Abbott Laboratories (NYSE:ABT) three years ago are up 39% - Yahoo Finance
Benchmark Initiates Coverage on Abbott Laboratories (NYSE:ABT) - MarketBeat
PDS Planning Inc Increases Stake in Abbott Laboratories $ABT - MarketBeat
Wealthstar Advisors LLC Decreases Position in Abbott Laboratories $ABT - MarketBeat
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
McKinley Carter Wealth Services Inc. Purchases 15,362 Shares of Abbott Laboratories $ABT - MarketBeat
Ramirez Asset Management Inc. Increases Position in Abbott Laboratories $ABT - MarketBeat
Aberdeen Group plc Purchases 81,094 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Trimmed by Coerente Capital Management - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Eastern Bank - MarketBeat
Horizon Bancorp Inc. IN Has $781,000 Stake in Abbott Laboratories $ABT - MarketBeat
Benchmark Initiates Coverage of Abbott Laboratories (ABT) with Buy Recommendation - Nasdaq
Abbott Laboratories (ABT): Exploring Valuation After Recent Shareholder Returns and Growth Prospects - simplywall.st
Abbott gets FDA breakthrough nod for dual-energy ablation catheter - MassDevice
Abbott is a steady Medtech company in an unsteady world, says Benchmark - Investing.com
Therapeutic Drug Monitoring (TDM) Market Size Expected to Reach USD 2.80 Bn by 2034 - GlobeNewswire Inc.
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus - The Globe and Mail
US Bancorp DE Has $390.37 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings - Nasdaq
Abbott (ABT) Receives Buy Rating with Bullish Outlook - GuruFocus
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott Laboratories: Diversified Growth and Strategic Investments Justify Buy Rating - TipRanks
Abbott Laboratories $ABT Shares Bought by Callan Family Office LLC - MarketBeat
Can Abbott Laboratories Deliver On Q3 Earnings Expectations? - RTTNews
Is Abbott Laboratories (ABL) stock cheap by valuation metrics2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
Pedialyte class action claims ‘healthy’ hydration drinks contain harmful artificial sweetener - Class Action Lawsuits
Abbott adds Laralab AI-based cardiac imaging tech - MassDevice
Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview) (ABT) - Seeking Alpha
First Merchants Corp Sells 4,988 Shares of Abbott Laboratories $ABT - MarketBeat
Maryland State Retirement & Pension System Has $11.45 Million Position in Abbott Laboratories $ABT - MarketBeat
Fluent Financial LLC Has $4.34 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):